23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline

shared a link

2024-11-12 01:07:34 -

WWW.WSJ.COM

The clinical trials 23andMe intends to wind-down include its two main therapeutic programs. The restructuring is expected to result in expenses of up to $12 million, and savings of more than $35 million per year, 23andMe said.

0 Comments 0 Shares 144 Views